Oddo confirms its 'outperform' rating on Carmat shares, with an unchanged target price of 28 euros, following the company's announcement yesterday of estimated sales of 10 to 13 million euros in 2023, with profitability in 2027.

This sales guidance will be supported by the ramp-up of implant centers throughout Europe (mainly in Germany and Italy). 30 centers should be operational by the end of this year", reports the analyst.

Carmat also expects to be able to market its artificial heart in the US by 2026.

The company's objectives are in line with our expectations, both in terms of short-term sales and long-term profitability. We are at the top end of the range for this annual guidance, including sales of 12 ME for this year", concludes the analyst.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.